JP2025515979A5 - - Google Patents

Info

Publication number
JP2025515979A5
JP2025515979A5 JP2024565108A JP2024565108A JP2025515979A5 JP 2025515979 A5 JP2025515979 A5 JP 2025515979A5 JP 2024565108 A JP2024565108 A JP 2024565108A JP 2024565108 A JP2024565108 A JP 2024565108A JP 2025515979 A5 JP2025515979 A5 JP 2025515979A5
Authority
JP
Japan
Prior art keywords
sequence
nucleotide sequence
polynucleotide construct
hybrid promoter
podocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024565108A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025515979A (ja
Filing date
Publication date
Priority claimed from EP22382421.0A external-priority patent/EP4273243A1/en
Application filed filed Critical
Publication of JP2025515979A publication Critical patent/JP2025515979A/ja
Publication of JP2025515979A5 publication Critical patent/JP2025515979A5/ja
Pending legal-status Critical Current

Links

JP2024565108A 2022-05-02 2023-04-28 ポドサイト特異的発現のための核酸コンストラクト及びベクター Pending JP2025515979A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22382421.0A EP4273243A1 (en) 2022-05-02 2022-05-02 Nucleic acid constructs and vectors for podocyte specific expression
EP22382421.0 2022-05-02
PCT/EP2023/061388 WO2023213738A1 (en) 2022-05-02 2023-04-28 Nucleic acid constructs and vectors for podocyte specific expression

Publications (2)

Publication Number Publication Date
JP2025515979A JP2025515979A (ja) 2025-05-22
JP2025515979A5 true JP2025515979A5 (enExample) 2026-05-12

Family

ID=82218428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024565108A Pending JP2025515979A (ja) 2022-05-02 2023-04-28 ポドサイト特異的発現のための核酸コンストラクト及びベクター

Country Status (8)

Country Link
US (1) US20250288696A1 (enExample)
EP (2) EP4273243A1 (enExample)
JP (1) JP2025515979A (enExample)
KR (1) KR20250006979A (enExample)
CN (1) CN119677849A (enExample)
AU (1) AU2023266069A1 (enExample)
CA (1) CA3256851A1 (enExample)
WO (1) WO2023213738A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201900702D0 (en) * 2019-01-18 2019-03-06 Univ Bristol Therapy
GB202009039D0 (en) 2020-06-15 2020-07-29 Univ Bristol Therapy
GB202304841D0 (en) * 2023-03-31 2023-05-17 Purespring Therapeutics Ltd Promoter
GB202309909D0 (en) 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Regulatory elements
GB202309913D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, avv vectors, and pharmaceutical compositions for treating nephrotic syndrome
GB202309908D0 (en) * 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Polynucleotides, aav vectors, and pharmaceutical compositions for treating complement-mediated kidney diseases
GB202309914D0 (en) 2023-06-29 2023-08-16 Purespring Therapeutics Ltd Promoters
WO2025168940A1 (en) 2024-02-07 2025-08-14 Purespring Therapeutics Limited Vectors
GB202407863D0 (en) 2024-06-03 2024-07-17 Purespring Therapeutics Ltd Methods
WO2026024176A1 (en) * 2024-07-22 2026-01-29 The Trustees Of The Columbia University In The City Of New York Synthetic reporters for multiplexed detection of transcription factor activity
GB202414499D0 (en) 2024-10-02 2024-11-13 Purespring Therapeutics Ltd Methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017153606A1 (en) 2016-03-11 2017-09-14 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Nucleic acid constructs and vectors for oncoselective expression of a transgene
GB201900702D0 (en) 2019-01-18 2019-03-06 Univ Bristol Therapy
EP3914719A4 (en) * 2019-01-24 2023-04-05 Valorisation-HSJ, Limited Partnership Cell-specific transcriptional regulatory sequences and uses thereof
GB202003618D0 (en) 2020-03-12 2020-04-29 Univ Bristol Gene Therapy

Similar Documents

Publication Publication Date Title
ES3052719T3 (en) Polynucleotides and vectors for the expression of transgenes
JP2024009857A5 (enExample)
JP2022500066A5 (enExample)
JP2022508182A5 (enExample)
US10413598B2 (en) Factor IX gene therapy
IL273261B2 (en) Adeno-associated virus variant capsids and methods of using them
JP2024099770A5 (enExample)
JP2021512649A5 (enExample)
JP2021505133A5 (enExample)
JP2022547197A5 (enExample)
JP2018522529A5 (enExample)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2019513399A5 (enExample)
JP2022529631A5 (enExample)
JP7541027B2 (ja) 筋肉発現のためのハイブリッドプロモーター
JP2023514242A5 (enExample)
CN106459932B (zh) 高胆红素血症的治疗
JP2021534814A5 (enExample)
JP2021520837A5 (enExample)
JP2022524434A5 (enExample)
JP2022541070A5 (enExample)
JP2022551744A5 (enExample)
RU2018145010A (ru) Оптимизированные гены и экспрессионные кассеты cln1, и их применение
JP2023537358A5 (enExample)
CN114231532B (zh) 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用